RESEARCH & DEVELOPMENT
New product development continues to be our first priority and the primary ingredient in delivering value to our customers.
Product development is the foundation upon which Hi-Tech is built. The company maintains an ongoing commitment to reinvest in R&D and scientific personnel.
With twenty-three pharmaceutical scientists - six with Ph.Ds - we recently welcomed the addition of Dr. Kamel Egbaria as Chief Scientific Officer and Executive Vice President. Dr. Egbaria brings more than 30 years experience in the pharmaceutical industry with an emphasis on liquid products development and manufacturing.
Hi-Tech has state-of-the-art equipment for development of highly specialized dosage forms such as ophthalmic solutions and suspensions, and nasal sprays. We believe these products are likely to face limited competition, and deliver a greater return on investment for a longer period of time. Hi-Tech 's expertise in developing highly specialized dosage forms differentiates its product line from its competitors and builds strong relationships with its customers.
Going forward Hi-Tech will continue to focus on these areas to capitalize on the existing and growing R&D expertise, manufacturing infrastructure and industry reputation.
Hi-Tech's internal effort is complemented by various product development agreements with industry partners. These strategic arrangements include both fee-for-service contracts, as well as partnership arrangements where Hi-Tech will share scientific and financial resources with a pharmaceutical partner to develop a more complex product. These agreements allow the Company to diversify and supplement its pipeline by adding non-liquid dosage forms, such as tablets and capsules, and support Hi-Tech in funding high cost, high barrier to entry development projects.